Nov. 25, 2015
Japanese Solasia Pharma K.K. and Lee’s Pharmaceutical Holdings Limited announced on November 25, 2015 that they have entered into an exclusive license agreement for the commercialization and promotion of Sancuso® (granisetron transdermal delivery system) in China, excluding three major cities (Beijing, Shanghai and Guangzhou).
Under the terms of the agreement, the license includes the right to commercialize Sancuso® for the patients suffering from chemotherapy-induced nausea and vomiting (CINV).
Solasia obtained an exclusive license to develop and commercialize Sancuso® for Asian territories from ProStrakan and is currently waiting for approval from the China Food and Drug Administration.